Study on the Risk Signal Mining Related to Linezolid Based on the US Food and Drug Administration Adverse Event Reporting System
- Author:
- No author available
- Journal Title:
- Chinese Journal of Drug Abuse Prevention and Treatment
- Issue:
- 1
- DOI:
- 10.15900/j.cnki.zylf1995.2024.01.009
- Key Word:
- 药物不良反应;不良事件;药物不良事件报告系统;美国食品和药物管理局;数据挖掘;信号处理;计算机辅助;利奈唑胺;Adverse drug reaction;Adverse event;Adverse event reporting systems;United States Food and Drug Administration;Data mining;Signal processing;Computer assisted;Linezolid
Abstract： Objective:To mine and analyze the adverse event(AE)signals of linezolid,so as to provide reference for clinical safety application.Methods:The AE reports on linezolid included in the FDA Adverse Event Reporting System(FAEAS)data from the second quarter of 2010 to the third quarter of 2021were collected,and the AE risk signals were explored by using the report odds ratio(ROR)method.Results:A total of 93 preferred terms(PT)with linezolid as the primary suspect(PS)drug were collected.Seven PTs were marked as"unknown"in the drug instructions,two PTs were marked as"rare"in the drug instructions,eight PTs were marked as"infrequent"in the drug instructions,and one PT(hypoglycemia)was mentioned in the drug instructions but not classified.62 PTs were not included in the package inserts,of which 10 were related to infection and infectious diseases,9 were related to blood and lymphatic system diseases,and 7 were related to various examinations.Conclusion:The AEs that occurred after the listing of linezolid are more consistent with the categories included in the instructions.During the clinical use,attention should be paid to the 17 AEs and the risk of hypoglycemia that have been marked as"unknown""rare"and"infrequent"in the instructions.A total of 63 new suspicious risk signals were discovered this time,and more attention should be paid to such signals.
- [1]Toshiyuki, Sakaeda,Akiko, Tamon,Kaori, Kadoyama,etc.Data mining of the public version of the FDA Adverse Event Reporting System.[J].2013,10(7).
- [2]白延宁,王莉,孙宝,等.利奈唑胺不良反应的文献统计分析[J].2022,42(20).
- [3]Pea, Federico.Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications[J].2018,57(2).
- [4]Mori, Nobuaki,Kamimura, Yoshio,Kimura, Yuki,etc.Comparative analysis of lactic acidosis induced by linezolid and vancomycin therapy using cohort and case-control studies of incidence and associated risk factors[J].2018,74(4).
- [5]Seyed Mohammad Reza, Hashemian,Tayebeh, Farhadi,Mojdeh, Ganjparvar.Linezolid: a review of its properties, function, and use in critical care.[J].2018,12(Spec).
- [6]Luo, Zhuanbo,Xu, Ning,Wang, Yun,etc.Linezolid-induced pure red cell aplasia: a case report and literature review[J].2018,46(11).
- [7]Jae Hyoung, Im,Ji Hyeon, Baek,Hea Yoon, Kwon,etc.Incidence and risk factors of linezolid-induced lactic acidosis.[J].2015,31.
- [8]Rucker JC,Hamilton SR,Bardenstein D,etc.Linezolid-associated toxic optic neuropathy.[J].2006,66(4).
- [9]Karkow, Diana C.,Kauer, Jill F.,Ernst, Erika J..Incidence of Serotonin Syndrome With Combined Use of Linezolid and Serotonin Reuptake Inhibitors Compared With Linezolid Monotherapy[J].2017,37(5).
- [10]Oh, Danielle H.,Motorna, Olga,Kong, Jun Beng,etc.Linezolid-associated reticulocytopenia[J].2016,95(12).
- [11]Hochberg AM,Pearson RK,O'Hara DJ,etc.Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.[J].2009,32(2).